Skip to main content
Article thumbnail
Location of Repository

The relationship between bisphosphonate use and demographic characteristics of male osteoporosis patients

By Alev Cevikoi, Ebru Umay, Sevgi Polat, Oznur Ecerkale and Aytul Cakci
Topics: Clinical Science
Publisher: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
OAI identifier: oai:pubmedcentral.nih.gov:3093787
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2008). Adherence to alendronate in male veterans. Osteoporos Int.
    2. Alendronate Phase III Osteoporosis Treatment Study Group. Ten years’ experience with alendronate for osteoporosis in postmenopausal women.
    3. (2006). Assessment of compliance with osteoporosis treatment and its consequences in a managed care population.
    4. Biologic half-life of bisphosphonates.
    5. (1993). Bisphosphonates in osteoporosis: an introduction. Osteoporosis Int.
    6. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.
    7. (2006). Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int.
    8. (2005). Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin.
    9. (2006). Compliance with medication therapy for postmenopausal osteoporosis. Osteoporos Int.
    10. Consensus development conference: prophylaxis and treatment of osteoporosis.
    11. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
    12. Design of the POSSIBLE UStrade mark Study: postmenopausal women’s compliance and persistence with osteoporosis medications. Osteoporos Int. 2009;20:463-72, doi: 10.1007/s00198-008-0674-3. Male osteoporosis and bisphosphonates Cevıkol A et al.
    13. Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate.
    14. (1997). Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int.
    15. (2006). Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int.
    16. Treatment of Osteoporosis in Clinical Practice (TOP) Study Group. Determinants of adherence to osteoporosis treatment in clinical practice.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.